The merger effectively ends Passage Bio as an independent entity. Current shareholders face massive dilution with only 7% pro forma ownership. The CVRs offer a speculative tailwind from legacy asset monetization but are highly uncertain. Monitor the shareholder vote and Nasdaq listing approval; if the deal closes, PASG will trade as a Remix Therapeutics entity with a new pipeline focus on REM-422.
Price Chart
Executive Summary
Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones, but the massive dilution and effective change of control make this a highly negative event for current PASG holders.
Key Financial Metrics
Key Facts
- Passage Bio shareholders will own approximately 7% of the combined company post-merger, with Remix shareholders (including PIPE investors) owning ~93%
- Concurrent PIPE of $69,999,999.28 plus convertible notes totaling at least $99,929,000 in gross proceeds
- Remix Equity Value set at $226M, Passage Equity Value at $20M in the merger exchange ratio
- Passage will change its name to Remix Therapeutics, Inc. and board/management will be replaced by Remix designees
- Contingent Value Rights (CVRs) issued to Passage shareholders for potential payments from legacy asset monetization (GM1 and MLD programs) through 2028
- Passage's existing gene therapy programs (PBFT02) are being wound down or divested as Legacy Assets
Financial Impact
Pre-merger Passage shareholders diluted to ~7% ownership of combined entity; combined company receives $100M+ in new capital; CVRs provide speculative upside from legacy asset payments (80% of GM1 payments and 100% of MLD payments, less deductions)
Risk Factors
- Deal may fail to close if Passage shareholders vote against the issuance or charter amendment
- CVR payments may be zero if Gemma does not make milestone payments or if Permitted Deductions consume proceeds
- Combined company's success depends entirely on Remix's unapproved drug REM-422, which carries clinical and regulatory risk
- Potential stockholder litigation challenging the merger terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-077306 |
| Document: tm2618476d1_ex10-6.htm | 0001104659-26-077306 |
| Document: tm2618476d1_ex10-4.htm | 0001104659-26-077306 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | S-4/A / 425 | $4.75 $5.00 | ▼ −5.26% | ▼ −6.41% | $4.33 (+8.84%) |
Sep 3, 2026 29d ago | 8-K | $4.75 $5.00 | ▲ +5.26% | ▲ +6.41% | $4.33 (−8.84%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
Jun 24, 2026 14w ago | 8-K | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
May 27, 2026 18w ago | 8-K | $5.71 $6.00 | ▼ −5.08% | ▼ −4.76% | $4.33 (+24.17%) |
Apr 20, 2026 23w ago | 8-K | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.33 (−30.72%) |
Apr 20, 2026 23w ago | Press Release | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.33 (−30.72%) |
Apr 7, 2026 25w ago | DEFA14A | $8.22 $10.86 | ▲ +32.20% | ▲ +26.87% | $4.33 (−47.29%) |
Mar 3, 2026 30w ago | Press Release | $8.00 $8.51 | ▲ +6.38% | ▲ +6.85% | $4.33 (−45.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access